2. Search Result
Search Result
Results for "

thermal nociception

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18732A
    L-NMMA acetate
    10+ Cited Publications

    Tilarginine acetate; Methylarginine acetate

    		 NO Synthase Neurological Disease Inflammation/Immunology Cancer
    L-NMMA (Tilarginine) acetate is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA acetate inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production . L-NMMA acetate alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA acetate is applicable to research related to nociception, bone cancer pain, and myopia .
    L-NMMA acetate
  • HY-103368
    Eact
    1 Publications Verification

    		 Chloride Channel Neurological Disease
    Eact is a selective and potent activator of TMEM16A, directly activates the TRPV1 channels in sensory nociceptors and produces itch, acute nociception and thermal hypersensitivity .
    Eact
  • HY-18732
    L-NMMA
    Maximum Cited Publications
    11 Publications Verification

    Tilarginine; Methylarginine

    		 NO Synthase Neurological Disease Inflammation/Immunology Cancer
    L-NMMA (Tilarginine) is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production . L-NMMA alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA is applicable to research related to nociception, bone cancer pain, and myopia .
    L-NMMA
  • HY-116005
    A-286501

    		Adenosine Kinase Neurological Disease Inflammation/Immunology
    A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC50 value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents .
    A-286501
  • HY-B0352B
    (R)-Mirtazapine

    (R)-Org3770; (R)-6-Azamianserin

    		 5-HT Receptor Neurological Disease
    (R)-Mirtazapine ((R)-Org3770) is a R( )-enantiomer of Mirtazapine with antinociceptive properties in an animal model of acute thermal nociception. (R)-Mirtazapine is a 5-HT3 receptor antagonist. (R)-Mirtazapine is mainly metabolized by CYP3A4 .
    (R)-Mirtazapine
  • HY-B0352A
    (S)-Mirtazapine

    (S)-Org3770; (S)-6-Azamianserin

    		 5-HT Receptor Neurological Disease
    (S)-Mirtazapine ((S)-Org3770) is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception. (S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2 .
    (S)-Mirtazapine
  • HY-B0352BS
    (R)-Mirtazapine-d3

    (R)-Org3770 d3; (R)-6-Azamianserin d3

    		 Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    (R)-Mirtazapine-d3 is a deuterium labeled (R)-Mirtazapine. (R)-Mirtazapine is a R(−)-enantiomer of Mirtazapine with antinociceptive properties in an animal model of acute thermal nociception. (R)-Mirtazapine is a 5-HT3 receptor antagonist. (R)-Mirtazapine is mainly metabolized by CYP3A4[1].
    (R)-Mirtazapine-d3
  • HY-B0352AS
    (S)-Mirtazapine-d3

    (S)-Org3770 d3; (S)-6-Azamianserin d3

    		 5-HT Receptor Neurological Disease
    (S)-Mirtazapine-d3 is a deuterium labeled (S)-Mirtazapine. (S)-Mirtazapine is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception.(S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2[1].
    (S)-Mirtazapine-d3
  • HY-18732C
    L-NMMA hydrochloride

    Tilarginine hydrochloride; Methylarginine hydrochloride

    		 NO Synthase Endogenous Metabolite Cardiovascular Disease Cancer
    L-NMMA (Tilarginine) hydrochloride is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA hydrochloride inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production . L-NMMA hydrochloride alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA hydrochloride is applicable to research related to nociception, bone cancer pain, and myopia .
    L-NMMA hydrochloride
  • HY-18732B
    L-NMMA citrate

    Methylarginine citrate; Tilarginine citrate

    		 NO Synthase Endogenous Metabolite Cardiovascular Disease Cancer
    L-NMMA (Tilarginine) citrate is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA citrate inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production . L-NMMA citrate alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA citrate is applicable to research related to nociception, bone cancer pain, and myopia .
    L-NMMA citrate
  • HY-18732AR
    L-NMMA acetate (Standard)

    Tilarginine acetate (Standard); Methylarginine acetate (Standard)

    		 Reference Standards NO Synthase Cardiovascular Disease Cancer
    L-NMMA (Tilarginine) acetate (Standard) is the analytical standard of L-NMMA acetate (HY-18732A). This product is intended for research and analytical applications. L-NMMA (Tilarginine) acetate is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA acetate inhibits three subtypes, namely nNOS, eNOS, and iNOS, and reduces NO production . L-NMMA acetate alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA acetate is applicable to research related to nociception, bone cancer pain, and myopia .
    L-NMMA acetate (Standard)
  • HY-103368R
    Eact (Standard)

    		Reference Standards Chloride Channel Neurological Disease
    Eact (Standard) is the analytical standard of Eact (HY-103368). This product is intended for research and analytical applications. Eact is a selective and potent activator of TMEM16A, directly activates the TRPV1 channels in sensory nociceptors and produces itch, acute nociception and thermal hypersensitivity .
    Eact (Standard)
  • HY-183857
    DD-161515

    		TRP Channel Neurological Disease
    DD-161515 is a TRPV1/VR1 inhibitor with an IC50 of 0.7 μM in rats. DD-161515 binds to an allosteric site of TRPV1 distinct from that of capsaicin, blocks channel opening, inhibits receptor-mediated calcium ion influx, reduces the excitability of peripheral sensory nerve fibers, and thereby inhibits nociception induced by heat and transmission of chemically induced pain signals. DD-161515 can be used in studies related to inflammatory pain .
    DD-161515
  • HY-182517
    AG1529

    		TRP Channel Inflammation/Immunology
    AG1529 is a TRPV1 inhibitor and capsaicinoid-based soft agent with a human TRPV1 IC50 of 0.9-0.93 μM. AG1529 reversibly blocks capsaicin-evoked TRPV1 activation, binds to the TRPV1 capsaicin binding site, moderately affects pH-induced TRPV1 gating, and does not alter voltage- or heat-mediated TRPV1 responses. AG1529 suppresses TRPV1-mediated neuronal excitability, reduces capsaicin- and pH-evoked neuronal firing, abolishes histaminergic and inflammation-mediated TRPV1 sensitization. AG1529 exhibits anti-nociceptive and antipruritic effects, attenuates in vivo hyperalgesia and pruritus, dose-dependently reduces acute histaminergic itch in rodents, and mildly blocks hTRPA1 and hTRPM8 channel activity. AG1529 undergoes hydrolysis and dermal deactivation, minimizes TRPV1-associated side reactions, does not evoke capsaicin-like burning sensation, and does not disrupt physiological thermal regulation. AG1529 can be used for the research of inflammatory cutaneous nociception and acute histaminergic pruritus .
    AG1529

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: